Medication Cost-Savings Toolkit for Nurse Care Managers
Version 1.0 (Founding Edition)
Prepared by Derek Sanz, PharmD
Purpose: Education + operational support for nurse care management teams
Cover Page
Medication Cost-Savings Toolkit
for Nurse Care Managers
Reduce medication cost barriers with practical workflows your team can use this week.
Includes:
- Top 25 high-cost classes with lower-cost pathways
- Step-therapy + prior auth quick-reference
- Patient cost-barrier script bank
- 1-page deprescribing opportunity checklist
- Monthly update tracker template
Founding Edition
Page 2 — How to Use This Toolkit (5-Minute Start)
Who this is for
- Nurse care managers
- Small care teams
- Clinical operations leaders supporting medication affordability workflows
What this toolkit is designed to do
- Speed up triage when patients report medication affordability barriers
- Standardize handoffs to prescribers/pharmacists
- Improve follow-through and closed-loop communication
Fast workflow
- Identify barrier (cost, coverage, denial, refill friction)
- Use quick-reference (class alternatives + PA/step requirements)
- Route clinical decision to licensed prescriber/pharmacist
- Close loop with patient and document outcome
30-day success signals
- Fewer unresolved cost barrier cases
- Faster case turnaround for PA/step edits
- More consistent patient follow-up and adherence support
Page 3–8 — Top 25 High-Cost Classes → Practical Lower-Cost Pathways
Use note: This table supports operational triage. Final therapy decisions must be made by licensed clinicians.
| # | High-Cost Class (Examples) | Practical Lower-Cost Pathways (context-dependent) | NCM Operational Notes | Patient Copay Assistance |
|---|---|---|---|---|
| 1 | GLP-1 receptor agonists | Metformin, sulfonylureas, TZDs, basal insulin (as appropriate) | PA common; capture trial/failure history | Check manufacturer savings card (commercial only), PAP for uninsured, and Medicare Extra Help screening. |
| 2 | SGLT2 inhibitors | Metformin-based intensification pathways | Consider comorbidity context | Use brand copay card when eligible; verify plan preferred NDC; screen for PAP/340B options. |
| 3 | DPP-4 inhibitors | Metformin/sulfonylurea options | Often non-preferred tiers | Run real-time benefit check and coupon eligibility; escalate to PAP if cash cost remains high. |
| 4 | Insulin analog brands | Human insulin pathways (if clinically appropriate) | Reinforce safety + dosing education | Prioritize $35 insulin cap pathways, manufacturer programs, and pharmacy-level discount adjudication. |
| 5 | ICS/LABA inhalers | Preferred formulary inhalers + generic ICS pathways | Device education is key | Compare inhaler-specific copay cards and preferred inhaler tiering before switch counseling. |
| 6 | Triple inhaler therapies | Stepwise component regimens | Step edits common | Use combination-product coupons, then check if separate preferred components lower total out-of-pocket cost. |
| 7 | LAMA/LABA combinations | Preferred alternatives by plan | Coverage variability high | Check per-product savings card and plan-preferred alternatives in same class to reduce copay. |
| 8 | DOACs | Warfarin in select appropriate cases | INR logistics may be barrier | Assess DOAC coupon eligibility, 30-day free trial offers, PAP, and foundation support where available. |
| 9 | New antiplatelet brands | Generic alternatives where appropriate | Confirm indication/duration | Use temporary copay support during high-risk post-ACS period; reassess step-down timing with prescriber. |
| 10 | PCSK9 inhibitors | Max-tolerated statin ± ezetimibe before escalation | Robust PA documentation needed | Initiate manufacturer copay card at start, use specialty pharmacy support hub, and apply for PAP if denied. |
| 11 | Brand omega-3 therapies | Generic pathways based on indication | Verify TG/ASCVD context | Check coupons and preferred formulations; avoid non-covered brands when equivalent covered option exists. |
| 12 | ARNI / selected HF brands | ACEi/ARB evidence-based alternatives where appropriate | Prescriber alignment required | Use HF brand copay programs, PAP referrals, and specialty/mail pharmacy cost optimization. |
| 13 | CGRP migraine preventives | Traditional preventive options first-line | Step therapy often required | Use bridge programs, copay cards, and manufacturer enrollment portals to avoid treatment gaps. |
| 14 | New migraine abortives | Generic triptan/NSAID pathways when suitable | Screen contraindications | Activate trial vouchers/copay cards first fill; document response to support continued coverage. |
| 15 | Brand ADHD products | Generic stimulant/non-stimulant options | Supply + formulary shifts | Check school-year coupon limits, DAW penalties, and preferred generic substitution options. |
| 16 | Atypical antipsychotic brands | Generic antipsychotic alternatives | Monitor metabolic effects | Use behavioral health PAP pathways and case-manager-assisted enrollment for high-need patients. |
| 17 | Brand antidepressants | Generic SSRI/SNRI pathways | Taper/switch plans matter | Apply copay cards for transition periods; switch to preferred generics when clinically stable. |
| 18 | Brand sleep agents | Generic + non-pharm options | Fall/cognitive risk review | Use short-term coupon support only; prioritize lowest-cost safe option for chronic use. |
| 19 | Newer AED brands | Established generic AED pathways where appropriate | No abrupt changes | If no switch is appropriate, pursue PAP and neurologist support letters for financial hardship review. |
| 20 | Brand GERD therapies | Generic PPI/H2 strategies | Step edits common | OTC/generic conversion plus FSA/HSA counseling can substantially lower monthly spend. |
| 21 | Brand constipation meds | Generic osmotic/stimulant protocols first | Prior trial details help | Use first-fill vouchers where available while documenting generic trial outcomes for PA support. |
| 22 | Biologics (autoimmune/IBD) | Biosimilar/formulary-preferred pathways | Benefit design complexity | Engage manufacturer hubs, copay cards, infusion-center assistance, and independent foundation screening. |
| 23 | Brand derm topicals | Generic topical alternatives | Quantity limits frequent | Apply derm copay cards and optimize day-supply/quantity to reduce refill frequency and cost spikes. |
| 24 | Brand ophthalmic drops | Formulary generic drops | Refill burden impacts adherence | Use eye-drop coupon programs and preferred bottle-size/NDC selection to minimize monthly copay. |
| 25 | Brand thyroid/hormonal products | Generic equivalents when clinically appropriate | Product consistency matters | If brand is required, enroll in manufacturer savings and 90-day supply pricing optimization. |
Quick triage prompts
- Is this primarily coverage or out-of-pocket cost?
- What has already been tried (name, dose, duration, result)?
- What documentation is needed to move this case today?
Page 9 — Step-Therapy + Prior Authorization Quick-Reference
Common PA triggers
- Brand request when preferred generic exists
- Missing prior trial/failure details
- Quantity above plan limit
- Insufficient diagnosis/supporting context
Documentation checklist
- Diagnosis + indication
- Prior meds tried + duration
- Outcomes (ineffective, intolerant, contraindicated)
- Relevant clinical context/labs where needed
- Why requested option is necessary now
NCM escalation flow
- Confirm rejection reason at pharmacy
- Capture required data points
- Send concise summary to prescriber/pharmacist
- Track due date and patient callback
- Document final outcome and unresolved barriers
Copy-ready provider handoff line
“Patient reports unaffordable cost for [medication]. Plan indicates [PA/step/non-formulary]. Prior therapy history: [details]. Request review for preferred lower-cost option or PA submission.”
Page 10–12 — Patient Conversation Script Bank (Cost Barrier)
Core script formula
Acknowledge → Assess → Offer options → Commit next step
Script examples
1) “I can’t afford this.”
“Thanks for telling me. Let’s work this now so you’re not stuck. I’ll check covered alternatives and route this to your care team today, then update you by [time].”
2) “I’m skipping doses to make it last.”
“Thanks for being honest—this is important. Let’s urgently review safer, affordable options with your clinician so your treatment stays on track.”
3) “Insurance denied it.”
“Got it. Denials often need targeted documentation. I’ll help gather what’s needed and coordinate next steps with your care team.”
4) “I don’t want to switch because this works.”
“That makes sense. We’ll try to preserve what works while addressing cost barriers. Your clinician can decide whether coverage support or a safer alternative is best.”
5) “I’m overwhelmed/confused.”
“You’re not alone—this is complicated. I’ll simplify your options and make sure you know the next step and timing.”
6) “I stopped taking it.”
“Thank you for sharing that. Let’s help you re-start with an affordable, manageable plan. I’ll coordinate with your clinician today.”
Close-the-loop callback template
“Update: [status]. Next action: [action]. I’ll check back by [date/time]. If pickup cost changes, contact us so we can adjust quickly.”
Page 13 — 1-Page Deprescribing Opportunity Checklist
Patient snapshot
- Conditions:
- Total medication count:
- Recent utilization:
- Patient-reported cost concern: Yes / No
Opportunity signals (check all that apply)
- Duplicate therapy
- No clear ongoing indication
- High-cost option with clinically reasonable lower-cost path
- Side effects reducing adherence
- Complex regimen causing confusion
- Goals-of-care mismatch
- Chronic PRN overuse
- Potential drug-disease or drug-drug concern
Routing flags
- Prescriber review needed
- Pharmacist med rec needed
- Specialist input needed
- Shared decision conversation needed
Patient readiness prompts
- “What matters most right now: cost, side effects, simplicity, or symptom control?”
- “Which medication feels hardest to keep up with?”
- “Would you be open to discussing lower-cost options with your clinician?”
Action plan
- Candidate medications for review:
- Routed to:
- Date routed:
- Follow-up date:
- Outcome: continued / adjusted / stopped / pending
Page 14 — Monthly Update Tracker (Google Sheets Template)
Recommended tabs
- Class_Watchlist
- PA_Step_Changes
- Script_Performance_Log
- Cases_and_Outcomes
- FAQ_and_Bonus_Pages
Required columns by tab
Class_Watchlist: Month, Class, Cost driver, Preferred pathways, Payer friction, Owner, Notes
PA_Step_Changes: Date, Payer/Plan, Medication, Change type, Required documentation, Effective date
Script_Performance_Log: Date, Scenario, Script used, Response, Next step, 14-day outcome
Cases_and_Outcomes: Case ID, Barrier type, Intervention, Days to resolution, Final status, Follow-up complete
FAQ_and_Bonus_Pages: Question, Draft answer, Add to bonus?, Owner, Publish date
Page 15 — FAQ
Is this clinical advice?
No. This is educational and operational support, not patient-specific medical advice.
Will this fit every payer?
No. Plan rules vary. The toolkit is designed to help teams adapt quickly.
Who should make final treatment decisions?
Licensed prescribers/clinicians with patient-specific context.
Required Disclaimer (Final Page + Footer)
This toolkit is for educational and operational support purposes only. It does not provide patient-specific medical advice, diagnosis, or treatment recommendations. Clinical decisions must be made by licensed professionals using individual patient context, current evidence, organizational policies, and payer-specific requirements.
Appendix — Gumroad Product Description (Paste-Ready)
Medication Cost-Savings Toolkit for Nurse Care Managers
A practical, no-fluff toolkit to help care teams reduce medication cost barriers quickly.
You get:
- Top 25 high-cost classes with lower-cost pathway guidance
- Step-therapy + PA quick-reference
- Patient cost-barrier script bank
- Deprescribing opportunity checklist
- Monthly tracker templates (Google Sheets)
Best for: Nurse care managers, small care teams, clinical ops leads.
Format: PDF + editable template structure.
Launch: $49 founding pricing (first 25), then $79.